^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

CCR5 receptor antagonist

7d
Cellular context and ligand class shape CXCR4-CCR5 heteromerization in live cells. (PubMed, Res Sq)
Agonists induced transient heteromerization coupled to receptor internalization, while antagonists, especially plerixafor together with maraviroc, stabilized persistent surface-associated complexes. Molecular dynamics simulations in asymmetric bilayers resembling MDA-MB-231 and MCF-10A membranes identified cholesterol-enriched receptor interfaces that prolong CXCR4-CCR5 dimer lifetimes in MDA-like membranes. These results show that GPCR heteromerization is not an intrinsic fixed property of receptor pairs, but an emergent behavior shaped by cell state, lipid environment, and ligand input.
Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
Selzentry (maraviroc) • plerixafor
8d
C-C motif chemokine 3 interferes with oligodendrocyte maturation in the brain. (PubMed, Biochem Biophys Res Commun)
These abnormalities were ameliorated by maraviroc treatment. Collectively, CCL3 interferes with oligodendrocyte maturation, thereby delaying axonal myelination and resulting in neural circuit dysfunction mediated by VPA.
Journal
|
CCL3 (C-C Motif Chemokine Ligand 3)
|
Selzentry (maraviroc)
10d
Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals (clinicaltrials.gov)
P2, N=70, Not yet recruiting, Federal University of São Paulo | Trial primary completion date: Jul 2026 --> Jan 2027
Trial primary completion date
|
CD4 (CD4 Molecule) • IL4 (Interleukin 4)
|
Selzentry (maraviroc)
20d
CCL5 improves radiation resistance through activation of the AMPK/mTOR pathway in adenoid cystic carcinoma. (PubMed, J Transl Med)
CCL5 promotes radioresistance in HNACC through maintenance of AMPK/mTOR-dependent autophagy. Targeting the CCL5/CCR5 axis enhances radiosensitivity and represents a promising therapeutic strategy.
Journal
|
CCL5 (Chemokine (C-C motif) ligand 5)
|
Selzentry (maraviroc)
22d
GCO 19-1754: Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
P2, N=48, Completed, Icahn School of Medicine at Mount Sinai | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Aug 2025
Trial completion • Trial completion date
|
Opdivo (nivolumab) • BMS-813160 • BMS-986253
24d
The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER) (clinicaltrials.gov)
P2, N=66, Active, not recruiting, CytoDyn, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
RAS wild-type
|
Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • Vyrologix (leronlimab)
29d
SALIENT-AD: Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease (clinicaltrials.gov)
P2, N=20, Recruiting, Weill Medical College of Cornell University | Not yet recruiting --> Recruiting
Enrollment open
|
Vyrologix (leronlimab)
1m
Enrollment change
|
Opdivo (nivolumab) • BMS-813160 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)
1m
Enhancing CAR-T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF-Mediated Angiogenesis. (PubMed, Adv Sci (Weinh))
Importantly, combining CCL5-knockout CAR-T cells with the CCR5 inhibitor maraviroc significantly enhanced antitumor efficacy. These findings reveal a mechanism constraining CAR-T function in solid tumors and suggest promising combination strategies to improve therapeutic outcomes.
Journal
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha)
|
Selzentry (maraviroc)
1m
New P2 trial
|
Vyrologix (leronlimab)
2ms
New trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Vyrologix (leronlimab)
3ms
Chemokine-defined macrophage niches establish spatial organization of tumor immunity. (PubMed, Nat Immunol)
During neoantigen vaccination, CCR5 blockade with maraviroc selectively inhibited antigen-bearing moDC migration, enhancing dendritic cell-mediated antitumor immunity. These findings showed how macrophage lineage and spatial compartmentalization govern tumor immunity and identified strategies to preserve protective IM functions, while disrupting macrophage-driven immunosuppression.
Journal
|
CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CCL2 (Chemokine (C-C motif) ligand 2) • ITGAM (Integrin, alpha M) • MRC1 (Mannose Receptor C-Type 1)
|
Selzentry (maraviroc)